ATE471315T1 - Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten - Google Patents
Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheitenInfo
- Publication number
- ATE471315T1 ATE471315T1 AT02773770T AT02773770T ATE471315T1 AT E471315 T1 ATE471315 T1 AT E471315T1 AT 02773770 T AT02773770 T AT 02773770T AT 02773770 T AT02773770 T AT 02773770T AT E471315 T1 ATE471315 T1 AT E471315T1
- Authority
- AT
- Austria
- Prior art keywords
- 17beta
- androgen
- piperidine
- treatment
- type
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title 1
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33006601P | 2001-10-17 | 2001-10-17 | |
| PCT/US2002/032979 WO2003033487A1 (en) | 2001-10-17 | 2002-10-15 | Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE471315T1 true ATE471315T1 (de) | 2010-07-15 |
Family
ID=23288179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02773770T ATE471315T1 (de) | 2001-10-17 | 2002-10-15 | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6969718B2 (de) |
| EP (1) | EP1436281B1 (de) |
| JP (1) | JP4309761B2 (de) |
| CN (1) | CN1571782A (de) |
| AR (1) | AR036812A1 (de) |
| AT (1) | ATE471315T1 (de) |
| CA (1) | CA2463626C (de) |
| DE (1) | DE60236743D1 (de) |
| ES (1) | ES2347643T3 (de) |
| MX (1) | MXPA04003611A (de) |
| PE (1) | PE20030705A1 (de) |
| WO (1) | WO2003033487A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345146T3 (es) * | 2002-11-18 | 2010-09-16 | Schering Corporation | Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| AU2003293555A1 (en) | 2002-12-17 | 2004-07-29 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| TW200528110A (en) * | 2003-12-17 | 2005-09-01 | Schering Corp | Pharmaceutical compositions |
| WO2005063247A1 (en) * | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| WO2007016496A2 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| AU2014300894A1 (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| WO2016102775A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
| US10413557B2 (en) | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| SG11201911776PA (en) | 2017-06-08 | 2020-01-30 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
| EP3724178B1 (de) * | 2017-12-15 | 2024-05-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopiperidin-derivate zur behandlung von krebs |
| CA3122049C (en) | 2018-12-05 | 2023-10-17 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| US12611406B2 (en) | 2020-06-19 | 2026-04-28 | Inthera Bioscience AG | Oxopiperazine derivatives for the treatment of cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| DE2304153A1 (de) | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Substituierte piperazin- und homopiperazinderivate |
| DE2304154A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Verfahren zur herstellung von substituierten piperazin- bzw. homopiperazinderivaten |
| DE3590389T1 (de) | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
| PH30747A (en) | 1989-03-10 | 1997-10-17 | Endorech Inc | Combination therapy for the treatment of estrogen sensitive disease. |
| DK0595796T3 (da) | 1989-07-07 | 2003-05-05 | Endorech Inc | Fremgangsmåde til behandling af androgen-relaterede sygdomme |
| CA2062973C (en) | 1989-07-07 | 2003-09-23 | Fernand Labrie | Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia |
| IL99320A (en) | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| ATE122673T1 (de) * | 1990-10-10 | 1995-06-15 | Schering Corp | Pyridin- und pyridin-n-oxid-derivate von diarylmethyl- piperidinen oder piperazinen, deren zusammensetzungen und anwendung. |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE69303605T2 (de) * | 1992-03-27 | 1997-01-23 | Schering Corp | Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung |
| EP0666856B1 (de) | 1992-10-28 | 2000-01-05 | MERCK SHARP & DOHME LTD. | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten |
| JPH08504435A (ja) | 1992-12-14 | 1996-05-14 | メルク シヤープ エンド ドーム リミテツド | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン |
| CZ285893B6 (cs) | 1993-05-17 | 1999-11-17 | Endorecherche Inc. | Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující |
| EP0702681A1 (de) | 1993-06-07 | 1996-03-27 | Merck & Co. Inc. | Spiro-substituierte azaringe als neurokinin antagonisten |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPH09507500A (ja) | 1994-01-13 | 1997-07-29 | メルク シヤープ エンド ドーム リミテツド | ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬 |
| EP0820452B1 (de) * | 1995-04-07 | 2003-06-04 | Schering Corporation | Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase |
| US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5945428A (en) | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| US6063926A (en) | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
| US6204265B1 (en) | 1998-12-23 | 2001-03-20 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
| CA2355744A1 (en) * | 1998-12-23 | 2000-07-06 | Schering Corporation | Novel inhibitors of farnesyl-protein transferase |
| DE60018707T2 (de) | 1999-01-25 | 2006-02-09 | Smithkline Beecham Corp. | Anti-androgene und verfahren zur behandlung von krankheiten |
| WO2001036386A1 (en) * | 1999-11-17 | 2001-05-25 | Sumitomo Pharmaceuticals Co., Ltd. | Diabetic remedy containing dipiperazine derivative |
| MY141661A (en) * | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
-
2002
- 2002-10-15 ES ES02773770T patent/ES2347643T3/es not_active Expired - Lifetime
- 2002-10-15 EP EP02773770A patent/EP1436281B1/de not_active Expired - Lifetime
- 2002-10-15 CN CNA02820557XA patent/CN1571782A/zh active Pending
- 2002-10-15 JP JP2003536227A patent/JP4309761B2/ja not_active Expired - Fee Related
- 2002-10-15 US US10/271,358 patent/US6969718B2/en not_active Expired - Fee Related
- 2002-10-15 CA CA2463626A patent/CA2463626C/en not_active Expired - Fee Related
- 2002-10-15 AT AT02773770T patent/ATE471315T1/de not_active IP Right Cessation
- 2002-10-15 PE PE2002001016A patent/PE20030705A1/es not_active Application Discontinuation
- 2002-10-15 WO PCT/US2002/032979 patent/WO2003033487A1/en not_active Ceased
- 2002-10-15 AR ARP020103851A patent/AR036812A1/es unknown
- 2002-10-15 MX MXPA04003611A patent/MXPA04003611A/es active IP Right Grant
- 2002-10-15 DE DE60236743T patent/DE60236743D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2347643T3 (es) | 2010-11-03 |
| EP1436281B1 (de) | 2010-06-16 |
| JP4309761B2 (ja) | 2009-08-05 |
| WO2003033487A1 (en) | 2003-04-24 |
| CA2463626C (en) | 2011-05-24 |
| MXPA04003611A (es) | 2004-07-30 |
| PE20030705A1 (es) | 2003-08-21 |
| JP2005506356A (ja) | 2005-03-03 |
| DE60236743D1 (de) | 2010-07-29 |
| US6969718B2 (en) | 2005-11-29 |
| AR036812A1 (es) | 2004-10-06 |
| CN1571782A (zh) | 2005-01-26 |
| US20030232837A1 (en) | 2003-12-18 |
| EP1436281A1 (de) | 2004-07-14 |
| CA2463626A1 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| ATE458753T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| ATE274494T1 (de) | Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| DE60216122D1 (de) | Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen | |
| ATE410421T1 (de) | P38 inhibitor und anwendungsverfahren dafür | |
| ATE385794T1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
| DE60223715D1 (de) | Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten | |
| EE200200442A (et) | Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks | |
| DE60122196D1 (de) | Synergistische antioxidans-kombination von delta tocols und polyphenolen | |
| DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| DE60221798D1 (de) | Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen | |
| ATE362928T1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
| DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
| DE60323765D1 (de) | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| DE60022867D1 (de) | 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen | |
| EP1476159A4 (de) | Zusammensetzungen und formulierungen von 9- nitrocamptothecin-polymorphen und verwendungsverfahren dafür | |
| DE60134009D1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |